uniQure (UQ1.F) shares fall 38% after updated Huntington’s disease gene therapy data
uniQure’s US-listed shares drop 38% to $24.25, the lowest level in over four months, after updated 36- and 48-month data for its Huntington’s disease gene therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.